Concepts (260)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Acute Coronary Syndrome | 34 | 2017 | 175 | 3.880 |
Why?
|
| Myocardial Infarction | 29 | 2018 | 412 | 2.890 |
Why?
|
| Emergency Service, Hospital | 38 | 2018 | 429 | 2.410 |
Why?
|
| Platelet Aggregation Inhibitors | 14 | 2015 | 82 | 1.940 |
Why?
|
| Chest Pain | 20 | 2018 | 175 | 1.850 |
Why?
|
| Anticoagulants | 13 | 2015 | 120 | 1.310 |
Why?
|
| Body Surface Potential Mapping | 4 | 2012 | 12 | 1.140 |
Why?
|
| Electrocardiography | 26 | 2016 | 562 | 1.130 |
Why?
|
| Risk Assessment | 23 | 2016 | 1300 | 1.020 |
Why?
|
| Emergency Medicine | 6 | 2010 | 117 | 0.910 |
Why?
|
| Myocardial Ischemia | 8 | 2012 | 83 | 0.910 |
Why?
|
| Critical Pathways | 5 | 2018 | 49 | 0.840 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 13 | 2013 | 32 | 0.790 |
Why?
|
| Hospitalists | 3 | 2008 | 7 | 0.730 |
Why?
|
| Emergency Treatment | 5 | 2010 | 42 | 0.700 |
Why?
|
| Registries | 15 | 2016 | 278 | 0.700 |
Why?
|
| Humans | 76 | 2018 | 29013 | 0.620 |
Why?
|
| Practice Guidelines as Topic | 13 | 2011 | 373 | 0.600 |
Why?
|
| Middle Aged | 52 | 2018 | 10805 | 0.580 |
Why?
|
| Angina, Unstable | 6 | 2007 | 17 | 0.570 |
Why?
|
| Aged | 45 | 2018 | 9462 | 0.550 |
Why?
|
| Male | 57 | 2018 | 17768 | 0.540 |
Why?
|
| Decision Support Techniques | 4 | 2017 | 104 | 0.520 |
Why?
|
| Female | 55 | 2018 | 18114 | 0.510 |
Why?
|
| Myocardial Revascularization | 6 | 2016 | 37 | 0.490 |
Why?
|
| Health Services Accessibility | 3 | 2010 | 231 | 0.480 |
Why?
|
| Troponin | 10 | 2016 | 79 | 0.480 |
Why?
|
| Thrombosis | 3 | 2009 | 60 | 0.470 |
Why?
|
| Angina Pectoris | 3 | 2013 | 19 | 0.450 |
Why?
|
| Coronary Disease | 7 | 2007 | 197 | 0.440 |
Why?
|
| Professional Competence | 1 | 2012 | 16 | 0.440 |
Why?
|
| Pattern Recognition, Automated | 1 | 2012 | 34 | 0.430 |
Why?
|
| Peptide Fragments | 8 | 2015 | 420 | 0.420 |
Why?
|
| United States | 23 | 2016 | 3604 | 0.420 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2012 | 46 | 0.420 |
Why?
|
| Cardiology | 4 | 2016 | 71 | 0.410 |
Why?
|
| Academic Medical Centers | 2 | 2010 | 150 | 0.410 |
Why?
|
| Guideline Adherence | 8 | 2011 | 110 | 0.410 |
Why?
|
| Coronary Thrombosis | 2 | 2008 | 15 | 0.390 |
Why?
|
| Algorithms | 4 | 2012 | 461 | 0.390 |
Why?
|
| Severity of Illness Index | 6 | 2016 | 863 | 0.390 |
Why?
|
| Exercise Test | 5 | 2016 | 194 | 0.380 |
Why?
|
| Transportation of Patients | 1 | 2010 | 20 | 0.380 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2010 | 29 | 0.380 |
Why?
|
| Coronary Artery Disease | 3 | 2008 | 358 | 0.370 |
Why?
|
| Enoxaparin | 7 | 2015 | 19 | 0.370 |
Why?
|
| Coronary Artery Bypass | 8 | 2015 | 100 | 0.370 |
Why?
|
| Time Factors | 16 | 2016 | 1997 | 0.370 |
Why?
|
| Education, Medical, Continuing | 5 | 2014 | 45 | 0.360 |
Why?
|
| Cardiology Service, Hospital | 3 | 2015 | 22 | 0.360 |
Why?
|
| Hirudins | 8 | 2015 | 19 | 0.350 |
Why?
|
| Clinical Protocols | 4 | 2016 | 95 | 0.350 |
Why?
|
| Sensitivity and Specificity | 8 | 2017 | 531 | 0.350 |
Why?
|
| Heparin | 7 | 2013 | 75 | 0.350 |
Why?
|
| Heart Diseases | 2 | 2011 | 97 | 0.340 |
Why?
|
| Adrenergic beta-Antagonists | 4 | 2009 | 59 | 0.330 |
Why?
|
| Creatine Kinase, MB Form | 7 | 2007 | 9 | 0.330 |
Why?
|
| Antithrombins | 3 | 2015 | 3 | 0.320 |
Why?
|
| Fibrinolytic Agents | 5 | 2009 | 70 | 0.320 |
Why?
|
| Adult | 21 | 2018 | 8391 | 0.320 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2008 | 35 | 0.320 |
Why?
|
| Continuity of Patient Care | 1 | 2008 | 64 | 0.310 |
Why?
|
| Treatment Outcome | 15 | 2015 | 3099 | 0.310 |
Why?
|
| Aspirin | 6 | 2010 | 61 | 0.310 |
Why?
|
| Predictive Value of Tests | 10 | 2017 | 784 | 0.300 |
Why?
|
| Hemorrhage | 6 | 2015 | 90 | 0.290 |
Why?
|
| Syncope | 1 | 2006 | 24 | 0.270 |
Why?
|
| Clinical Competence | 2 | 2009 | 307 | 0.270 |
Why?
|
| Patient Selection | 2 | 2011 | 257 | 0.260 |
Why?
|
| Credentialing | 1 | 2004 | 8 | 0.250 |
Why?
|
| Patient Discharge | 4 | 2015 | 168 | 0.250 |
Why?
|
| Politics | 1 | 2004 | 20 | 0.250 |
Why?
|
| North Carolina | 8 | 2016 | 1422 | 0.240 |
Why?
|
| Pacemaker, Artificial | 1 | 2004 | 17 | 0.240 |
Why?
|
| Postural Balance | 1 | 2016 | 160 | 0.240 |
Why?
|
| Recombinant Proteins | 8 | 2015 | 248 | 0.240 |
Why?
|
| Ticlopidine | 5 | 2009 | 17 | 0.230 |
Why?
|
| Hospital Mortality | 7 | 2009 | 186 | 0.230 |
Why?
|
| Pesticides | 1 | 2016 | 189 | 0.230 |
Why?
|
| Reproducibility of Results | 5 | 2016 | 724 | 0.230 |
Why?
|
| Clinical Trials as Topic | 4 | 2008 | 298 | 0.230 |
Why?
|
| Occupational Exposure | 1 | 2016 | 224 | 0.230 |
Why?
|
| Emigrants and Immigrants | 1 | 2016 | 235 | 0.220 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2013 | 1218 | 0.220 |
Why?
|
| Survival Analysis | 6 | 2013 | 440 | 0.220 |
Why?
|
| Transients and Migrants | 1 | 2016 | 281 | 0.220 |
Why?
|
| Aged, 80 and over | 13 | 2016 | 3712 | 0.220 |
Why?
|
| Delivery of Health Care | 3 | 2014 | 142 | 0.220 |
Why?
|
| Risk Factors | 12 | 2017 | 3509 | 0.220 |
Why?
|
| Heart Conduction System | 3 | 2008 | 69 | 0.210 |
Why?
|
| Atherosclerosis | 1 | 2008 | 691 | 0.210 |
Why?
|
| Troponin T | 4 | 2007 | 57 | 0.210 |
Why?
|
| Peptides | 4 | 2013 | 118 | 0.210 |
Why?
|
| Patient Care Team | 2 | 2014 | 124 | 0.200 |
Why?
|
| Cohort Studies | 6 | 2017 | 1674 | 0.200 |
Why?
|
| Prospective Studies | 7 | 2016 | 2010 | 0.190 |
Why?
|
| Logistic Models | 10 | 2010 | 725 | 0.190 |
Why?
|
| Evidence-Based Medicine | 5 | 2011 | 207 | 0.190 |
Why?
|
| Patient Admission | 2 | 2011 | 53 | 0.190 |
Why?
|
| Acute Disease | 8 | 2011 | 239 | 0.180 |
Why?
|
| Hispanic Americans | 1 | 2016 | 904 | 0.180 |
Why?
|
| Coronary Angiography | 4 | 2018 | 136 | 0.180 |
Why?
|
| Creatine Kinase | 3 | 2003 | 10 | 0.180 |
Why?
|
| Isoenzymes | 3 | 2003 | 63 | 0.170 |
Why?
|
| Quality of Health Care | 3 | 2010 | 134 | 0.160 |
Why?
|
| Odds Ratio | 7 | 2011 | 446 | 0.160 |
Why?
|
| Early Diagnosis | 2 | 2008 | 61 | 0.160 |
Why?
|
| Diagnostic Errors | 2 | 2009 | 42 | 0.150 |
Why?
|
| Troponin C | 1 | 2017 | 9 | 0.150 |
Why?
|
| Drug Therapy, Combination | 4 | 2015 | 273 | 0.150 |
Why?
|
| Observation | 2 | 2013 | 23 | 0.140 |
Why?
|
| Triage | 3 | 2009 | 65 | 0.140 |
Why?
|
| Pyridines | 2 | 2013 | 78 | 0.140 |
Why?
|
| Prognosis | 7 | 2016 | 1362 | 0.140 |
Why?
|
| Diagnostic Imaging | 1 | 2016 | 88 | 0.130 |
Why?
|
| Death | 1 | 2015 | 41 | 0.130 |
Why?
|
| Health Care Costs | 1 | 2016 | 108 | 0.130 |
Why?
|
| Cause of Death | 3 | 2016 | 219 | 0.130 |
Why?
|
| Hospitalization | 3 | 2010 | 417 | 0.130 |
Why?
|
| Retrospective Studies | 9 | 2016 | 3107 | 0.130 |
Why?
|
| Age Factors | 5 | 2016 | 1105 | 0.130 |
Why?
|
| Documentation | 2 | 2004 | 32 | 0.130 |
Why?
|
| Heart Failure | 4 | 2007 | 567 | 0.120 |
Why?
|
| Follow-Up Studies | 7 | 2016 | 2106 | 0.120 |
Why?
|
| Decision Making | 1 | 2016 | 180 | 0.120 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2016 | 462 | 0.120 |
Why?
|
| Double-Blind Method | 3 | 2013 | 501 | 0.120 |
Why?
|
| Cyclic N-Oxides | 1 | 2013 | 8 | 0.120 |
Why?
|
| Vasodilator Agents | 1 | 2013 | 54 | 0.110 |
Why?
|
| Troponin I | 3 | 2007 | 17 | 0.110 |
Why?
|
| Diagnosis, Differential | 3 | 2016 | 493 | 0.110 |
Why?
|
| Observer Variation | 1 | 2012 | 96 | 0.110 |
Why?
|
| Combined Modality Therapy | 3 | 2008 | 524 | 0.110 |
Why?
|
| Syndrome | 4 | 2007 | 66 | 0.110 |
Why?
|
| Quality Assurance, Health Care | 2 | 2010 | 61 | 0.110 |
Why?
|
| Health Personnel | 2 | 2011 | 111 | 0.110 |
Why?
|
| Single-Blind Method | 1 | 2012 | 165 | 0.110 |
Why?
|
| Singapore | 5 | 2016 | 10 | 0.110 |
Why?
|
| Cardiovascular Agents | 2 | 2009 | 18 | 0.100 |
Why?
|
| Hospital Costs | 1 | 2011 | 36 | 0.100 |
Why?
|
| Health Expenditures | 1 | 2011 | 61 | 0.100 |
Why?
|
| Length of Stay | 4 | 2015 | 291 | 0.100 |
Why?
|
| Regional Health Planning | 1 | 2010 | 8 | 0.100 |
Why?
|
| Patient Care | 1 | 2011 | 33 | 0.100 |
Why?
|
| Inpatients | 1 | 2011 | 64 | 0.100 |
Why?
|
| Thrombolytic Therapy | 2 | 2008 | 59 | 0.100 |
Why?
|
| Women | 1 | 2010 | 10 | 0.100 |
Why?
|
| Organizational Innovation | 1 | 2010 | 30 | 0.100 |
Why?
|
| Critical Care | 1 | 2011 | 114 | 0.100 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2014 | 325 | 0.100 |
Why?
|
| Program Development | 1 | 2010 | 85 | 0.090 |
Why?
|
| Minority Groups | 1 | 2010 | 69 | 0.090 |
Why?
|
| Program Evaluation | 1 | 2010 | 175 | 0.090 |
Why?
|
| Case-Control Studies | 3 | 2016 | 855 | 0.090 |
Why?
|
| Polysaccharides | 1 | 2009 | 13 | 0.090 |
Why?
|
| Point-of-Care Systems | 1 | 2009 | 33 | 0.090 |
Why?
|
| Internet | 2 | 2007 | 156 | 0.080 |
Why?
|
| Emergency Medical Services | 2 | 2010 | 157 | 0.080 |
Why?
|
| Cardiovascular Diseases | 1 | 2016 | 1007 | 0.080 |
Why?
|
| Postoperative Hemorrhage | 1 | 2008 | 38 | 0.080 |
Why?
|
| Attitude of Health Personnel | 2 | 2009 | 161 | 0.080 |
Why?
|
| Myocardial Reperfusion | 1 | 2007 | 10 | 0.080 |
Why?
|
| Drug Utilization Review | 1 | 2007 | 17 | 0.080 |
Why?
|
| Healthcare Disparities | 1 | 2009 | 153 | 0.080 |
Why?
|
| Incidence | 3 | 2016 | 1105 | 0.080 |
Why?
|
| Vascular Surgical Procedures | 1 | 2008 | 91 | 0.080 |
Why?
|
| Multicenter Studies as Topic | 4 | 2007 | 92 | 0.070 |
Why?
|
| Recurrence | 1 | 2007 | 235 | 0.070 |
Why?
|
| Sex Factors | 2 | 2005 | 626 | 0.070 |
Why?
|
| Insurance, Health | 2 | 2004 | 91 | 0.070 |
Why?
|
| Confidence Intervals | 3 | 2011 | 140 | 0.070 |
Why?
|
| Ventricular Function, Left | 1 | 2007 | 194 | 0.070 |
Why?
|
| Asian Continental Ancestry Group | 1 | 2005 | 110 | 0.060 |
Why?
|
| Professional Autonomy | 1 | 2004 | 6 | 0.060 |
Why?
|
| Reimbursement Mechanisms | 1 | 2004 | 11 | 0.060 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2004 | 18 | 0.060 |
Why?
|
| Specialty Boards | 1 | 2004 | 9 | 0.060 |
Why?
|
| Malpractice | 1 | 2004 | 20 | 0.060 |
Why?
|
| Cost Savings | 2 | 2016 | 32 | 0.060 |
Why?
|
| Medical Staff, Hospital | 1 | 2004 | 18 | 0.060 |
Why?
|
| Medically Uninsured | 1 | 2004 | 31 | 0.060 |
Why?
|
| Patient Transfer | 1 | 2004 | 34 | 0.060 |
Why?
|
| Survival Rate | 2 | 2016 | 795 | 0.060 |
Why?
|
| Costs and Cost Analysis | 2 | 2016 | 88 | 0.060 |
Why?
|
| Insurance Coverage | 1 | 2004 | 74 | 0.060 |
Why?
|
| Total Quality Management | 1 | 2002 | 19 | 0.060 |
Why?
|
| Aging | 1 | 2009 | 880 | 0.050 |
Why?
|
| ROC Curve | 2 | 2016 | 148 | 0.050 |
Why?
|
| Comorbidity | 3 | 2009 | 539 | 0.050 |
Why?
|
| American Medical Association | 2 | 2011 | 6 | 0.050 |
Why?
|
| Chi-Square Distribution | 2 | 2009 | 292 | 0.040 |
Why?
|
| Health Care Surveys | 2 | 2009 | 176 | 0.040 |
Why?
|
| Forecasting | 2 | 2010 | 133 | 0.040 |
Why?
|
| Immunoglobulin Fab Fragments | 2 | 2008 | 14 | 0.040 |
Why?
|
| Tyrosine | 2 | 2008 | 22 | 0.040 |
Why?
|
| Medical History Taking | 1 | 2016 | 32 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 2 | 2008 | 196 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2016 | 113 | 0.030 |
Why?
|
| Research Design | 2 | 2007 | 285 | 0.030 |
Why?
|
| Echocardiography, Stress | 1 | 2015 | 22 | 0.030 |
Why?
|
| Sex Distribution | 2 | 2006 | 185 | 0.030 |
Why?
|
| Age Distribution | 2 | 2006 | 197 | 0.030 |
Why?
|
| Evaluation Studies as Topic | 2 | 2004 | 39 | 0.030 |
Why?
|
| Multivariate Analysis | 2 | 2007 | 636 | 0.030 |
Why?
|
| Consensus | 2 | 2004 | 68 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2016 | 331 | 0.030 |
Why?
|
| Stents | 2 | 2008 | 171 | 0.030 |
Why?
|
| Health Resources | 1 | 2014 | 33 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 2013 | 73 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2013 | 85 | 0.030 |
Why?
|
| Efficiency, Organizational | 1 | 2013 | 18 | 0.030 |
Why?
|
| Risk | 1 | 2013 | 289 | 0.030 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2003 | 79 | 0.030 |
Why?
|
| Patient Readmission | 1 | 2013 | 105 | 0.030 |
Why?
|
| Telecommunications | 1 | 2011 | 5 | 0.030 |
Why?
|
| Peer Review, Health Care | 1 | 2011 | 4 | 0.030 |
Why?
|
| Radionuclide Imaging | 1 | 2011 | 23 | 0.030 |
Why?
|
| Staff Development | 1 | 2011 | 13 | 0.030 |
Why?
|
| Coronary Care Units | 1 | 2011 | 4 | 0.030 |
Why?
|
| Models, Economic | 1 | 2011 | 18 | 0.030 |
Why?
|
| Dobutamine | 1 | 2011 | 43 | 0.030 |
Why?
|
| Drug Costs | 1 | 2011 | 42 | 0.030 |
Why?
|
| Adenosine | 1 | 2011 | 41 | 0.030 |
Why?
|
| Echocardiography | 1 | 2011 | 140 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2013 | 706 | 0.020 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2010 | 6 | 0.020 |
Why?
|
| State Health Plans | 1 | 2010 | 4 | 0.020 |
Why?
|
| Myocardium | 1 | 2011 | 170 | 0.020 |
Why?
|
| Heart | 1 | 2011 | 161 | 0.020 |
Why?
|
| Linear Models | 1 | 2011 | 425 | 0.020 |
Why?
|
| Bradycardia | 1 | 2009 | 15 | 0.020 |
Why?
|
| Drug Utilization | 1 | 2009 | 47 | 0.020 |
Why?
|
| Hypotension | 1 | 2009 | 47 | 0.020 |
Why?
|
| Benchmarking | 1 | 2009 | 25 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2010 | 149 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2009 | 246 | 0.020 |
Why?
|
| Thiophenes | 1 | 2008 | 21 | 0.020 |
Why?
|
| Atherectomy | 1 | 2008 | 4 | 0.020 |
Why?
|
| Piperazines | 1 | 2008 | 56 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2011 | 1353 | 0.020 |
Why?
|
| Coronary Stenosis | 1 | 2007 | 28 | 0.020 |
Why?
|
| Quality Indicators, Health Care | 1 | 2007 | 55 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2007 | 129 | 0.020 |
Why?
|
| Preoperative Care | 1 | 2008 | 110 | 0.020 |
Why?
|
| Diagnosis-Related Groups | 1 | 2006 | 11 | 0.020 |
Why?
|
| Systole | 1 | 2007 | 87 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2011 | 871 | 0.020 |
Why?
|
| Medical Records | 1 | 2006 | 68 | 0.020 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2007 | 136 | 0.020 |
Why?
|
| Data Collection | 1 | 2006 | 163 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2006 | 73 | 0.020 |
Why?
|
| Physicians | 1 | 2006 | 134 | 0.020 |
Why?
|
| Stroke Volume | 1 | 2007 | 278 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 2003 | 93 | 0.010 |
Why?
|
| Catheter Ablation | 1 | 2004 | 62 | 0.010 |
Why?
|
| Creatinine | 1 | 2003 | 173 | 0.010 |
Why?
|
| Continental Population Groups | 1 | 2004 | 221 | 0.010 |
Why?
|
| Prevalence | 1 | 2005 | 892 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2003 | 469 | 0.010 |
Why?
|
| African Americans | 1 | 2003 | 1373 | 0.010 |
Why?
|